நெக்ஸஸ் ட்க்ஸ் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நெக்ஸஸ் ட்க்ஸ் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நெக்ஸஸ் ட்க்ஸ் இன்க் Today - Breaking & Trending Today

DGAP-News: SphingoTec Accelerates Growth with Direct Sales


DGAP-News: SphingoTec Accelerates Growth with Direct Sales
vom 20.05.2021, 10:00 Uhr
Bild: pixabay.com
SphingoTec Accelerates Growth with Direct Sales
20.05.2021 / 10:00
The issuer is solely responsible for the content of this announcement.
SphingoTec to expand the commercialization strategy by establishing a sales division and appointing new head of sales
Tailored diagnostic solutions for point of care use
Innovative proprietary biomarkers and standard parameters available on the fully automated Nexus IB10 platform
Hennigsdorf/Berlin, Germany, May 20, 2021 - Diagnostics company SphingoTec GmbH ( SphingoTec ) announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic solutions. SphingoTec will sell directly to healthcare providers its Nexus IB10 point of care platform together with a broad portfolio of assays. The rapid tests include commonly used parameters ....

San Diego , United States , Andreas Bergmann , Sphingotec Gmbh , Steffen Hohmann , Sphingotec Gmb , Ruxandra Lenz , Corporate Action Strategic Company Decision , Nexus Dx Inc , Distribution Services , Strategic Company Decision , Tec Accelerates Growth , Direct Sales , Dipeptidyl Peptidase , Tec Gmbh , Manager Marketing , Corporate News , Regulatory Announcements , Dgap News , Action Strategic , சான் டியாகோ , ஒன்றுபட்டது மாநிலங்களில் , ஆண்ட்ரியாஸ் பெர்க்மேன் , நெக்ஸஸ் ட்க்ஸ் இன்க் , விநியோகம் சேவைகள் , மூலோபாய நிறுவனம் முடிவு ,

Endothelial function biomarker bio-ADM for risk stratification and management of COVID-19 patients


 E-Mail
Aachen, Germany and Hennigsdorf/Berlin, Germany, May 4, 2021 - German University Hospital Uniklinik RWTH Aachen ( Uniklinik RWTH Aachen ) and diagnostics company SphingoTec GmbH ( SphingoTec ) today announced that the endothelial function biomarker bio-ADM aids in the early risk stratification and management of patients suffering from severe COVID-19, in need for escalated intensive care treatment (1). A team lead by the clinical researchers at Uniklinik RWTH Aachen has shown that high bio-ADM levels indicate the severity of the acute respiratory distress syndrome (ARDS), the subsequent need for organ support, and poor outcomes in severely ill COVID-19 patients. Bioactive Adrenomedullin (bio-ADM) is a hormone regulating endothelial function and has been previously validated in over 35.000 patients with diseases where endothelial dysfunction plays a key role, such as sepsis, septic shock, cardiogenic shock, and acute heart failure. ....

San Diego , United States , Bioactive Adrenomedullin , Andreas Bergmann , Sphingotec Gmbh , Gernot Marx , Department Of Operative Intensive Care Medicine , University Hospital , German University Hospital Uniklinik , Nexus Dx Inc , University Hospital Uniklinik , Operative Intensive Care Medicine , Intermediate Care , Simont P , Critically Ill Patients , Biologically Active Adrenomedullin , Predicts Hemodynamic Support Requirement , Mortality During , Ter Maaten , Tec Gmbh , Dipeptidyl Peptidase , சான் டியாகோ , ஒன்றுபட்டது மாநிலங்களில் , ஆண்ட்ரியாஸ் பெர்க்மேன் , பல்கலைக்கழகம் மருத்துவமனை , நெக்ஸஸ் ட்க்ஸ் இன்க் ,